Pfizer Inc. Q4 FY2026 Earnings Call Summary

PFE NYSE Healthcare 📅 2026-02-03 🟡 Neutral

⚠️ Not financial advice. This summary is AI-generated for informational purposes only. Always do your own research before making investment decisions. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-04-30 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Pfizer delivered solid full-year 2025 financial results, with revenues of $62.6 billion and adjusted diluted EPS of $0.66, both surpassing analyst expectations for the period. The company is strategically pivoting towards its robust non-COVID pipeline and portfolio, reaffirming its 2026 financial guidance despite anticipated declines in COVID-19 product sales.

📊 Key Financial Metrics

Revenue $62.6B vs est. $59.5B to $62.5B ✅ Beat

EPS (Diluted) $0.66 vs est. $2.80 to $3.00 ✅ Beat

AI Sentiment 🟡 Neutral The company's strong non-COVID portfolio growth and robust pipeline investments are balanced by significant declines in COVID-19 product revenues and substantial asset impairments, indicating a period of strategic transition.

✅ What Went Well

✅ Robust growth in the non-COVID portfolio, achieving 6% operational revenue growth for full-year 2025, driven by key products like Abrysvo (up 136% operationally in Q4), Oncology biosimilars (up 76% operationally in Q4), and the Vyndaqel family (up 7% operationally in Q4).

✅ Significant pipeline advancement with 11 key pivotal study starts in 2025 and an ambitious plan for approximately 20 more in 2026, including promising ultra-long-acting obesity assets and a PD-1 x VEGF bispecific antibody, positioning Pfizer for long-term innovation and market leadership.

✅ Strong financial discipline leading to a solid 75.8% gross margin and effective capital allocation, including $10.4 billion invested in R&D and $8.8 billion in business development in 2025, alongside returning $9.8 billion to shareholders through dividends.

⚠️ Concerns & Risks

⚠️ Significant decline in COVID-19 product revenues, with Comirnaty down 35% operationally and Paxlovid down 70% operationally in Q4 2025, posing a substantial headwind to overall revenue growth as the market normalizes.

⚠️ Substantial intangible asset impairment charges totaling $4.4 billion in Q4 2025, reflecting changes in development plans and updated long-range commercial forecasts for several assets, including $1.6 billion for disitamab vedotin and $820 million for Tukysa, indicating challenges in certain pipeline assets.

⚠️ Anticipated revenue headwinds in 2026 from loss of exclusivity (LOE) for certain products, expected to negatively impact revenue by approximately $1.5 billion, alongside potential unfavorable impacts from Most-Favored-Nation drug pricing, TrumpRx, and currently imposed tariffs.

🔮 CEO / Management Guidance

Management reaffirmed its full-year 2026 financial guidance, projecting revenues in a range of $59.5 billion to $62.5 billion and adjusted diluted EPS between $2.80 and $3.00. This guidance anticipates approximately $5 billion in revenues from COVID-19 products and a negative revenue impact of about $1.5 billion due to loss of exclusivity for certain products. The company plans to initiate approximately 20 key pivotal trials in 2026, emphasizing strategic investment in its pipeline.

💬 Key Quote

With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts, and continued strategic investment to maximize our opportunities for industry-leading growth at the end of the decade. — Dr. Albert Bourla, Chairman and CEO of Pfizer

🏢 About Pfizer Inc.

Pfizer Inc. (PFE) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

PFE NYSE Healthcare All Pfizer Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

📁 More from Pfizer Inc.

View all earnings summaries for Pfizer Inc. →